FDA Investigator Shirley H Isbill

Shirley H Isbill has inspections in 9 countries as of 13 Dec 2022. Shirley H Isbill has collaborated with a combinined 1772 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
34
Last Inspection Date:
13 Dec 2022
Investigator Role:
FDA Investigator
Redica ID:
100006320
Country:
Canada, United States of America, Germany, United Kingdom of Great Britain and Northern Ireland, China, Belgium, Netherlands, Jordan, Japan
Co-Investigator(s):
Alanna Lmussawwir Bias, Alberto A Viciedo, Allen Lou, Amy L Singer, Ana S Cabrera, Andrew A Leboeuf, Ann Marie Montemurro, Annemarie B Randow, Annemarie Bodnar, Barbara L Rellahan, PhD, Bruce H Mccullough, Byungja E Marciante, Camille D Brown, Cara M Minelli, Catherine J Laufmann, Charles A Snipes, PhD, Charles I Ann, Christina N Maurino, Daniel J Grabicki, Deborah B Nixon, Douglas C Kovacs, Dr. S Nar Ali, PhD, Dr. Sriram Subramaniam, PhD, Dr. Zhou Chen (nmi), MD PhD, Emest F Bizjak, Eric J Cunningham, Eric Rothschild, Erin D Mccaffery, Gajendiran Mahadevan, PhD, Gene R Gunn, Helen B Ricalde, Helen Verdel, Jacqueline Mdiaz Albertini, Javier O Vega, Jean M Kelahan, Jennifer C Adams, John M Dietrick, Jose R Hernandez, Joseph F Mcginnis, RPh, Joshua P Wireman, Joy Rkozlowski Klena, Justine Tomasso, Karen E D'orazio, Kelli F Dobilas, Kenneth Miller, Kenneth V Miller, Kimberly Lewandowski Walker, Kinh Q Mac, Kip J Hanks, Kristy A Zielny, Laureen M Geniusz, Li Li, Liatte Kreuger, PharmD, Loretta Nemchik, Lori S Lawless, Makini Cobourne Duval, PhD, Marcelo O Mangalindan, Jr, Marea K Harmon, Martin K Yan, PhD, Martin Yau, Matt D Suedkamp, Melba T Rivera, Melba Trivera Clavell, Meyer J Slobotsky, Michael Serrano, Nancy A Bellamy, Nancy L Rolli, Nerizza B Guerin, Nerizza Dalena, Nicola M Fenty Stewart, Nina Yang, Niraj Mehta, Paul L Bellamy, Peter R Lenahan, Prabhu P Raju, Regina T Brown, Richmond K Yip, Ruben C Ayala, PharmD, Russell J Glapion, Sam H Haidar, PhD, Sandra Kershaw, Sarah Adella Fave, Sarah Forney, Shirley Isbill, Sidney B Priesmeyer, Simone E Pitts, Sinai Davis, Stephanie T Durso, Susan W Ting, Syed N Ali, Tania E Garcia, Tania E Vizcaino, Tawny L Colling, Terri L Dodds, Thomas J Arista, Wayne J Meyer, Yehualashet A Gessesse, Zi Qiang Gu

Shirley H Isbill's Documents

Publish Date Document Type Title
March, 2003 FDA 483 Response Colgate Palmolive Company - Form 483R, 2003-03-13
October, 2003 EIR Centurion Systems, Inc. - EIR, 2003-10-08
November, 2002 FDA 483 Gaetano Morelli, M.D. - Form 483, 2002-11-15
February, 2003 EIR Abbott Point Of Care Inc. - EIR, 2003-02-07
March, 2003 EIR Colgate Palmolive Company - EIR, 2003-03-06
May, 2002 EIR Yangzhou Pharmaceutical Ltd - EIR, 2002-06-19
November, 2000 EIR Gallagher Michael RDO - EIR, 2000-11-03
November, 2002 EIR Gaetano Morelli, M.D. - EIR, 2005-03-25
November, 2002 FDA 483 Gaetano Morelli, M.D. - Form 483, 2002-11-15
July, 2001 FDA 483 Berlin Medical Associates - Form 483, 2001-07-31
January, 2003 FDA 483 Hoffmann La Roche Inc - Form 483, 2003-01-09
March, 2003 FDA 483 Colgate Palmolive Company - Form 483, 2003-03-06
December, 2000 EIR Samuel Serfaty, M.D. - EIR, 2001-02-23
June, 2004 EIR Eisai Co., Ltd. - EIR, 2004-08-11
May, 2002 FDA 483 Yangzhou Pharmaceutical Ltd - Form 483, 2002-05-23
November, 2004 FDA 483 Response Astellas Pharma Inc. - Form 483R, 2005-01-03
May, 2002 FDA 483 Response Yangzhou Pharmaceutical Ltd - Form 483R, 2002-06-28
November, 2002 FDA 483 Response Gaetano Morelli, M.D. - Form 483R, 2002-12-02
July, 2001 EIR Berlin Medical Associates - EIR, 2001-07-31
January, 2003 EIR Hoffmann La Roche Inc - EIR, 2003-01-09
September, 2002 EIR Marchione, Victor MD - EIR, 2002-09-11
February, 2003 FDA 483 Abbott Point Of Care Inc. - Form 483, 2003-02-07
January, 2003 FDA 483 Response Hoffmann La Roche Inc - Form 483R, 2003-01-27
November, 2004 EIR Astellas Pharma Inc. - EIR, 2004-12-16

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more